Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change

被引:48
作者
Ngan, ETC
Lane, CJ
Ruth, TJ
Liddle, PF
机构
[1] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada
[2] TRIUMF, Positron Emiss Tomog Program, Vancouver, BC V6T 2A3, Canada
关键词
D O I
10.1136/jnnp.72.1.106
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Different symptom patterns have been shown to be associated with specific patterns of cerebral metabolic activity in schizophrenia. Treatment with various neuroleptic drugs results in decreased metabolism in frontal cortical regions. The temporal and regional relation between changes in metabolism and symptom improvement after treatment with risperidone was studied in eight previously unmedicated schizophrenic patients. Method: Cerebral metabolic activity was measured using PET before neuroleptic exposure, after the first dose of risperidone, and after 6 weeks of treatment. Pearson correlations were calculated For regions of significant change in metabolism and symptom change. Results: After 6 weeks of treatment significant deactivations were seen in the left lateral cortical frontal region and medial frontal cortex. Significant changes were detectable in the medial frontal region 90 minutes after the first dose of risperidone. Patients with higher baseline activity in the identified medial frontal cluster had higher baseline positive symptom scores and reduction in medial frontal metabolism was correlated with reduction in positive symptom score. Conclusion: The evidence suggests that the reduction in medial-frontal activity after treatment with risperidone is a direct effect of risperidone and not a consequence of symptom improvement. Reduction of medial frontal metabolism may be one of the physiological mechanisms by which risperidone alleviates symptoms of psychosis in schizophrenia.
引用
收藏
页码:106 / 110
页数:5
相关论文
共 30 条
[1]  
ANDREASEN NC, 1995, ARCH GEN PSYCHIAT, V52, P341
[2]   Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients [J].
Andreasen, NC ;
OLeary, DS ;
Flaum, M ;
Nopoulos, P ;
Watkins, GL ;
Ponto, LLB ;
Hichwa, RD .
LANCET, 1997, 349 (9067) :1730-1734
[3]   Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients [J].
Bartlett, EJ ;
Brodie, JD ;
Simkowitz, P ;
Schlosser, R ;
Dewey, SL ;
Lindenmayer, JP ;
Rusinek, H ;
Wolkin, A ;
Cancro, R ;
Schiffer, W .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (03) :337-343
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]  
Berman I, 1996, PSYCHOPHARMACOL BULL, V32, P95
[6]   POSITRON EMISSION TOMOGRAPHY STUDIES OF BASAL GANGLIA AND SOMATOSENSORY CORTEX NEUROLEPTIC DRUG EFFECTS - DIFFERENCES BETWEEN NORMAL CONTROLS AND SCHIZOPHRENIC-PATIENTS [J].
BUCHSBAUM, MS ;
WU, JC ;
DELISI, LE ;
HOLCOMB, HH ;
HAZLETT, E ;
COOPERLANGSTON, K ;
KESSLER, R .
BIOLOGICAL PSYCHIATRY, 1987, 22 (04) :479-494
[7]  
BUCHSBAUM MS, 1992, NEUROPSYCHOPHARMACOL, V6, P155
[8]  
BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P966
[9]  
BUCHSBAUM MS, 1992, CLIN NEUROPHARMACOL, V15, P472
[10]  
Cohen RM, 1997, ARCH GEN PSYCHIAT, V54, P481